Routine proxy notice with no immediate trading catalyst. The 10M share increase to the stock incentive plan could cause modest future dilution but is standard for growth-stage biotechs. Monitor the annual meeting outcome on June 10 for any unexpected voting results, particularly the say-on-pay vote and director elections.
Price Chart
Executive Summary
Ocular Therapeutix filed a DEFA14A (definitive additional proxy soliciting materials) providing notice of its 2026 Annual Meeting of Stockholders to be held on June 10, 2026. The meeting will include votes on electing two Class III directors, an advisory vote on executive compensation, approval of a stock incentive plan amendment to increase authorized shares by 10,000,000, and ratification of the independent auditor. This is a routine proxy notice with no material financial or strategic developments.
Key Facts
- Annual Meeting scheduled for June 10, 2026, at 8:30 AM ET, held virtually
- Stockholders to vote on election of two Class III directors: Pravin U. Dugel, M.D. and Merilee Raines
- Proposal to amend the 2021 Stock Incentive Plan to increase authorized shares by 10,000,000 shares
- Advisory vote on named executive officer compensation and frequency of future advisory votes (1 year recommended)
- Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026
- Board recommends 'For' votes on all proposals
- Record date and proxy deadline not specified in this notice
Financial Impact
Proposal to increase share authorization by 10,000,000 shares for equity compensation; no dollar amount disclosed
Risk Factors
- Potential dilution from 10M additional shares under the stock incentive plan
- No financial results or guidance provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001104659-26-053185 |
| Document: 0001104659-26-053185-index-headers.html | 0001104659-26-053185 |
| Document: 0001104659-26-053185-index.html | 0001104659-26-053185 |
| Document: 0001104659-26-053185.txt | 0001104659-26-053185 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | Insider Cluster | $10.90 $7.67 | ▼ −29.63% | ▼ −29.30% | $6.96 (−36.15%) |
Aug 26, 2026 5w ago | Insider Cluster | $10.82 $9.82 | ▼ −9.24% | ▼ −8.73% | $6.96 (−35.67%) |
Aug 3, 2026 8w ago | 8-K | $8.40 $10.49 | ▲ +24.88% | ▲ +23.64% | $6.96 (−17.14%) |
Jun 17, 2026 15w ago | Press Release | $9.64 $9.17 | ▼ −4.93% | ▼ −6.24% | $6.96 (−27.80%) |
Jun 12, 2026 16w ago | 8-K | $8.99 $9.88 | ▲ +9.90% | ▲ +10.65% | $6.96 (−22.58%) |
Jun 4, 2026 17w ago | Press Release | $8.80 $9.64 | ▲ +9.55% | ▲ +10.92% | $6.96 (−20.91%) |
May 28, 2026 18w ago | Insider Cluster | $9.01 $9.90 | ▲ +9.88% | ▲ +11.67% | $6.96 (−22.75%) |
May 5, 2026 21w ago | 8-K | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
May 5, 2026 21w ago | Press Release | $9.71 $8.31 | ▼ −14.42% | ▼ −19.37% | $6.96 (−28.32%) |
Apr 30, 2026 22w ago | DEFA14A | $9.43 $8.93 | ▼ −5.30% | ▼ −10.57% | $6.96 (−26.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access